Arthur Klausner
Chief Executive Officer
Management
Gem Pharmaceuticals Inc
United States of America
Biography
A seasoned life sciences venture capitalist and entrepreneur, Mr. Klausner has a total of 18 years of experience at Domain Associates and Pappas Ventures, where he was involved in the investment in and subsequent nurturing of a variety of biotechnology, specialty pharmaceutical, and medical device companies. He has been a board member at Santarus (acquired by Salix Pharmaceuticals), X-Ceptor (acquired by Exelixis), Orexigen (Nasdaq: OREX), and Syndax Pharmaceuticals, and a board observer at Peninsula Pharmaceuticals (acquired by Johnson & Johnson), Cerexa (acquired by Forest Laboratories), and Optherion. Previously CEO of Jade Therapeutics, Mr. Klausner currently serves on the Board of Directors of Cennerv Pharma, and on advisory boards for Neurotez, Dresner Partners, and the New York University Innovation Venture Fund. Mr. Klausner received his M.B.A. from the Stanford University Graduate School of Business and his undergraduate degree in Biology from Princeton University.
Research Interest
Investing in Lofe Sciences Companies
